Skip to main content

Beyond Chemotherapy and Immunotherapy in Thoracic Malignancies: Overcoming Resistance by Tackling New Molecular Pathways

69kviews
Editorial16 September 2022
Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways

of approximately 8-10 months and a median overall survival that falls below two years in both squamous and nonsquamous histologies [2][3][4][5][6]. Immune checkpoint inhibitors (ICIs) administered as monotherapy in selected patients with high programmed-death ligand 1 (PD-L1) expression achieve better outcomes that, nevertheless, confer long-term responses only in a minority of patients [7][8][9].Patients with advanced NSCLC who progress after chemoimmunotherapy, given either concurrently or sequentially, currently have limited treatment options. Second-line chemotherapy with docetaxel, administered alone or in combination with anti-angiogenic agents (ramucirumab, nindetanib), offers modest clinical outcomes [10,11]. ICIs given as monotherapy have been proven superior to docetaxel in patients progressing after first-line chemotherapy [12][13][14][15]. Recent advances in elucidating the molecular biology of the disease have led to the identification of molecular pathways that could be exploited therapeutically in an effort to improve outcomes by overcoming resistance to immunotherapy and chemotherapy [1]. The patterns of resistance to immunotherapy have been extensively studied and may involve primary or secondary resistance as well as intrinsic and extrinsic mechanisms encompassing diverse molecular pathways [16].Consequently, potential strategies to overcome acquired resistance may include, among others:-Combinations of immune checkpoint-modifying agents that either inhibit suppression of immune cells (antagonists) or activate the immune system (agonists). Examples include the synergistic activity of PD-(L) 1 inhibitors with anti-CTLA4 or anti-TIGIT monoclonal antibodies, as well as the combination with agonists of immune activation, such as OX-40 monoclonal antibodies [17] -Combinations of ICIs with molecular targeted agents, such as tyrosine kinase inhibitors, that interfere with diverse molecular pathways, including cellular proliferation, apoptosis regulation, inflammation, DNA repair, epigenetic modification and angiogenesis. Metabolic pathways that are often associated with immune regulation involve the mitogen-activated protein kinase (MAPK), the phosphatidyl-inositol -3-kinase (PI3K) and the signaling transducer and activator of transcription (STAT) molecular pathways [18] -Biotechnological advances have enabled the clinical development of novel molecules with unique properties, such as antibody-drug conjugates and bi-specific antibodies, that may act as "engagers" of the immune system to cancer cells, triggering thus the anti-tumor activity of the immune system against neoantigens [19,20] -Finally, the role of the tumor microenvironment and the identification of potential biomarkers of activity/resistance to novel treatment strategies is currently a field of active investigation to enhance anti-tumor immunity by studying the interaction of the tumor cells with the stroma and the surrounding host niche [21] In the current issue of Frontiers, we present eight (8) high-quality articles that evaluate the Discovering ways and strategies to overcome resistance to immunotherapy, chemotherapy and targeted agents is a constantly evolving research field. In this ever-lasting scientific endeavor, the only road to successful outcomes passes through sound scientific ratiional, robust pre-clinical experimentation and well-designed and executed clinical trials. The algorithmic use of potent biomarkers, including liquid biopsies, will likely assist in identifying the subgroups of patients who will benefit the most from each experimental strategy. The collective goal of these strategies will be to implement individualized treatment approaches after chemotherapy and immunotherapy failure, based on the unique biological characteristics and mechanisms of primary or acquired resistance for each one of our patients. This personalized approach paves the way for precision oncology, which is the optimal strategy to improve the lives of our patients.

2,214 views

3 citations

Lung cancer is the leading cause of cancer mortality worldwide. Immunotherapy has demonstrated clinically significant benefit for non-small-cell lung cancer, but innate (primary) or acquired resistance remains a challenge. Criteria for a uniform clinical definition of acquired resistance have been recently proposed in order to harmonize the design of future clinical trials. Several mechanisms of resistance are now well-described, including the lack of tumor antigens, defective antigen presentation, modulation of critical cellular pathways, epigenetic changes, and changes in the tumor microenvironment. Host-related factors, such as the microbiome and the state of immunity, have also been examined. New compounds and treatment strategies are being developed to target these mechanisms with the goal of maximizing the benefit derived from immunotherapy. Here we review the definitions of resistance to immunotherapy, examine its underlying mechanisms and potential corresponding treatment strategies. We focus on recently published clinical trials and trials that are expected to deliver results soon. Finally, we gather insights from recent preclinical discoveries that may translate to clinical application in the future.

17,941 views

62 citations

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
REVIEW
9 February 2022
Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
Fenglong Bie, 9 more and Shugeng Gao
Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) is an important pair of immune checkpoints (IC), which play an essential role in the immune escaping process of tumors. Anti-PD-1/PD-L1 immunotherapy can block the suppression effect of the immune system produced by tumor cells through the PD-1/PD-L1 axis and restore the pernicious effect of the immune system on tumor cells. The specific mechanism of anti-PD-1/PD-L1 immunotherapy is closely related to PI3K (phosphatidylinositol 3-kinase)/ AKT (AKT serine/threonine kinase 1), JNK (c-Jun N-terminal kinase), NF-kB (nuclear factor-kappa B subunit 1), and other complex signaling pathways. Patients receiving anti-PD-1/PD-L1 immunotherapy are prone to drug resistance. The mechanisms of drug resistance mainly include weakening recognition of tumor antigens by immune cells, inhibiting activation of immune cells, and promoting the production of suppressive immune cells and molecules. Anti-PD-1/PD-L1 immunotherapy plays a vital role in non-small cell lung cancer (NSCLC). It is essential to find better efficacy prediction-related biomarkers and screen patients suitable for immunotherapy. At present, common biomarkers related to predicting immune efficacy mainly include PD-L1 expression level in tumors, tumor mutation burden (TMB), microsatellite instability (MSI)/mismatch repair (MMR), mutations of driver gene, etc. However, the screening efficacy of each indicator is not ideal, and the combined application of multiple indicators is currently used. This article comprehensively reviews anti-PD-1/PD-L1 immunotherapy-related mechanisms, drug resistance-related mechanisms, and therapeutic efficacy-related predictive biomarkers.

8,977 views

45 citations

ORIGINAL RESEARCH
8 March 2022
The Effect of Extracellular Superoxide Dismutase (SOD3) Gene in Lung Cancer
Yundi Zhang, 5 more and Hua Sun

4,457 views

21 citations

ORIGINAL RESEARCH
31 January 2022
Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
Marc A. Schneider, 8 more and Sabina Janciauskiene

3,919 views

18 citations

ORIGINAL RESEARCH
23 December 2021
A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy
Jiaojiao Suo, 5 more and Jiang Zhu

2,276 views

1 citations

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
CLINICAL TRIAL
8 September 2021
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Chul Kim, 8 more and Giuseppe Giaccone
Background: Osimertinib is an effective first-line therapy option for EGFR-mutant NSCLC, but virtually all patients develop resistance. CRIPTO, through Src activation, has been implicated in resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. Dasatinib, a Src inhibitor, has shown preclinical synergy with EGFR-TKI therapy. Method: This is a single-arm phase I/II trial of osimertinib and dasatinib in treatment-naïve advanced EGFR-mutant NSCLC. A 3+3 design was used in the phase I to establish the recommended phase II dose (RP2D). Osimertinib 80 mg QD was combined with dasatinib 70 mg BID (DL2), 50 mg BID (DL1), 70 mg QD (DL-1), and 50 mg QD (DL-2). Results: Ten patients (DL2: 3, DL1: 6, DL -1: 1) were enrolled. 3 (50%) of 6 patients at DL1 experienced a DLT (grade 3 headaches/body pain, neutropenia, rash, one each). Common treatment-related adverse events included pleural effusion (n=10), diarrhea (n=8), rash (n=7), transaminitis (n=7), thrombocytopenia (n=7), and neutropenia (n=7). While the MTD was not determined by protocol-defined DLT criteria, DL-2 was chosen as the RP2D, considering overall tolerability. Nine (90%) patients had a PR, including 1 unconfirmed PR. Median PFS was 19.4 months and median OS 36.1 months. The trial was closed to accrual prematurely due to slow accrual after the approval of osimertinib as first-line therapy. Conclusions: The combination of dasatinib and osimertinib demonstrated anticancer activity. The treatment was limited by chronic toxicities mainly attributed to dasatinib. To improve the safety and tolerability of Src and EGFR co-inhibition, Src inhibitors with a more favorable safety profile should be utilized in future studies.

6,334 views

28 citations

ORIGINAL RESEARCH
6 September 2021
DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma
Didi Yuan, 7 more and Renkuan Tang

3,162 views

8 citations